Articles tagged with Breast Cancer
A waste disposal protein called p62 is responsible for disposing of damaged proteins in cells, preventing the accumulation of toxic waste that can promote cancer tumor growth. Researchers discovered that controlling p62 levels can stimulate autophagy and lead to tumor suppression.
Researchers discovered a protein profile that may accurately predict tamoxifen resistance in breast cancer patients. The study found that the extracellular matrix metalloproteinase inducer (EMMPRIN) was significantly associated with an earlier tumor progression and poor clinical outcome.
A team of scientists at The University of Texas M. D. Anderson Cancer Center has identified four new targets for breast cancer treatment, including three lysophosphatidic acid receptors and the enzyme autotaxin. These targets are found to be abnormally expressed in many types of cancer and have been shown to cause cancer.
Researchers at UNC Lineberger Comprehensive Cancer Center found a new protein SFRP2 that stimulates angiogenesis in various tumor sites. The discovery provides a potential target for developing new drugs to starve tumors of blood supply and destroy them.
A new study found that many breast cancer patients use antioxidant supplements, including high doses, during treatment. However, the effects on health and survival are poorly understood and the findings are mixed.
A study found that many women with breast cancer use antioxidant supplements during treatment, which may have mixed effects on their health and survival. Researchers recommend further research to determine the impact of antioxidant supplementation on breast cancer outcomes.
Researchers at U-M Comprehensive Cancer Center found that PTEN pathway affects growth of breast cancer stem cells and discovered a 90% reduction in stem cell population with perifosine treatment. This study suggests that targeting this pathway may improve current therapies for breast cancer
PTEN is often inactivated in breast cancer, leading to poor patient outcomes. Researchers found that a drug called perifosine specifically targets the breast cancer stem cell population by inhibiting the Akt pathway, reducing tumor-forming cells by up to 90%.
Researchers found a distinct link between the ABCC11 gene and excessively smelly armpits, wet earwax, and breast cancer risk. The study discovered that a specific SNP in the ABCC11 gene determines earwax type.
The I-SPY trial offers critical insights into locally advanced breast cancer, emphasizing the importance of not ignoring growing breast masses. The study found that most interval cancers are discovered between routine mammogram exams, suggesting a need for better screening strategies.
A study has identified a breast cancer gene called AGTR1 that is overexpressed in up to 20% of breast cancers and can be blocked by the blood pressure drug losartan. The researchers found that treatment with losartan shrunk tumors by 30% in mice, suggesting a potential new treatment option for women with AGTR1-positive breast tumors.
A new study found that taking a short break from postmenopausal hormone therapy does not lower the risk of false-positive mammogram results. However, it may help reduce breast density, making tumors harder to detect on X-rays.
Researchers have identified a molecule called PHD2 that regulates blood vessel growth and is often found at lower-than-normal levels in human tumors. Blocking PHD2 expression allows human cancer cells to grow more quickly, increasing tumor blood vessel formation.
In a phase I/II trial, combining trastuzumab and neratinib induced clinically meaningful responses in women with HER2-positive metastatic breast cancer who had progressed on previous trastuzumab-based therapies. Nine out of 33 patients (27%) achieved an objective response to the combination therapy.
A team of scientists and clinicians co-led by Joe Gray and Dennis Slamon will study three subtypes of breast cancer: estrogen receptor positive, HER2 positive, and triple negative. Their goal is to match a tumor's genetic profile with the best therapy, using cutting-edge biological, genomic, and computational techniques.
Five multi-disciplinary research teams will pursue innovative cancer treatments, combining laboratory scientists and physicians with a focus on rapid progress and collaboration. The funding model aims to eliminate barriers to creativity and collaboration, enabling diverse experts from institutions across the US to work together.
V. Craig Jordan, a renowned breast cancer scientist, has assembled a team of top researchers to tackle the complexities of breast cancer through a $73.7 million grant from Stand Up To Cancer. The 'Dream Team' aims to accelerate cancer treatment within three years by understanding the molecular diversity of human breast cancer.
Research from Northwestern University found Abraxane effectively prevents metastatic breast cancer progression and has fewer side effects compared to Taxotere. The study prolonged progression-free survival by almost seven months.
Researchers at Fred Hutchinson Cancer Center identified two proteins associated with chronic inflammation linked to long-term survival in breast cancer patients. Elevated levels of C-reactive protein and serum amyloid A are associated with reduced overall survival, regardless of patient age or tumor stage.
Researchers at Boston University School of Medicine found that conventional methods to adjust for confounding, such as restriction and multivariable regression, leave residual confounding because of unmeasured factors. Propensity scores and instrumental variable methods have limitations in resolving confounding by indication.
Breast cancer patients with high levels of C-reactive protein (CRP) and serum amyloid A (SAA) are more likely to die sooner or have their cancer return. Elevated CRP is also linked to increased risk of heart disease.
Two studies in the American Journal of Pathology demonstrate stromal caveolin-1 as a prognostic marker for breast cancer progression, correlating with reduced metastasis levels. Additionally, researchers have identified novel biomarkers for chronic kidney disease progression, predicting progressive renal fibrosis and glomerular filtrat...
A new study reveals that nearly one in four African American women with late-stage breast cancer refuse chemotherapy and radiation therapy. The authors emphasize the need for improved healthcare access and education to encourage treatment adherence. Further research is necessary to understand the factors contributing to this disparity.
A study at Dartmouth Hitchcock Medical Center found that nearly 20% of patients with recent breast cancer diagnoses had additional malignant tumors detected only by Breast MRI. The detection of these 'unsuspected' cancers is critical for patient health and survival.
Research suggests different invasive breast cancer subtypes have distinct etiologic pathways and prognoses. Patients with specific subtypes exhibit varying demographics, lifestyle traits, and risk factors, highlighting the need for refined tumor subtyping to elucidate development patterns.
A new study published in Journal of General Internal Medicine found that few women with family histories of hereditary breast or ovarian cancer are discussing genetic testing with their physicians. Most high-risk women are unaware of the available test or have not discussed it with their clinician.
A recent study published in Epidemiology found that hormone replacement therapy does not increase breast cancer risk for women with or without a family history. The research analyzed data from the Women's Health Initiative randomized trial and suggests that estrogen sensitivity may not be the causal pathway based on family history.
Vanderbilt University researchers have identified a gene signature linked to reduced relapse-free survival in breast cancer patients, especially those with estrogen receptor-positive tumors. The discovery suggests that assessing TGF-β signaling may aid in determining breast cancer prognosis and guiding treatment.
A new mathematical model developed at the University of Texas Health Science Center at Houston suggests that tumor growth and invasion can be predicted using biophysical laws. The model, which links molecular and cellular properties to tumor behavior, consistently reproduced patterns of tumor invasion observed in experiments and patien...
Researchers have identified a molecular link between sleep and weight gain, suggesting that targeting T-type calcium channels could be beneficial for weight loss. Additionally, studies on glucocorticoid hormones have revealed their protective effects on the heart during ischemia/reperfusion injury.
A study by Duke University Medical Center found that only 64% of low-income women with hormone receptor-positive breast cancer filled any prescriptions for hormonal therapy within 12 months after diagnosis. The researchers also discovered that 40% of the women stopped taking their medication regularly, and 20% stopped using it altogether.
The Pathfinder program, which focuses on body, mind, and spirit, has been found to improve distress and despair in women with metastatic breast cancer. The program provides patient navigation, counseling, and coping skills training, resulting in a higher quality of life for participants.
A study by M. D. Anderson Cancer Center researchers found that over one-third of metastatic breast cancer patients receive chemotherapy off-label, with 34.9% of women treated with an unapproved drug at some point during their care. The most common off-label chemotherapies noted were vinorelbine and gemcitabine, both shown to be efficac...
Researchers at the Mayo Clinic have found a triple drug combination to be an effective and tolerable option for treating metastatic HER2+ breast cancer. The regimen, which combines capecitabine, vinorelbine, and trastuzumab, has shown promising results in reducing tumor size and improving survival rates compared to traditional treatments.
Researchers identified cancer stem cells in breast cancer patients' bone marrow, which correlated with tumor's lymph node involvement and worse prognosis. The study suggests a need for novel biological therapies targeting these cells, and may lead to better monitoring of patients needing additional treatment.
A recent study found that chemotherapy in addition to surgery or radiation improves survival rates among older women with early-stage breast cancer. Combination therapy showed significantly better outcomes than single-drug treatment, with a 17% higher relapse-free survival rate at three years.
A review of phase I clinical trial designs and the association between lymphovascular invasion and breast cancer recurrence, highlighting the need for new methods to expedite drug development and improve patient outcomes.
A home-based diet and exercise program reduced the rate of functional decline among older, overweight long-term cancer survivors. The intervention group showed significant improvements in targeted behaviors and overall health-related quality of life compared to the control group.
Researchers at UNC identified the p18 gene as a potential cause of luminal-type breast cancers, which account for 70-80% of all cases. The study found that defects in this gene lead to uncontrolled cell growth and cancer.
Researchers have identified a genetic signature that can predict which breast cancer patients will respond well to treatment with epirubicin, a widely used form of chemotherapy. This signature may help ensure fewer women are exposed to severe side effects by identifying those most likely to benefit from treatment.
A new molecular biology-based technique has been shown to detect potential breast cancer spread with high accuracy, speed, and specificity. The Lymphoseek molecule binds to lymph node white blood cells, allowing for targeted detection of nearby 'sentinel nodes' that are most likely to contain cancer.
Researchers have identified a new prognostic factor in breast cancer patients, predicting early disease recurrence, metastasis, and patient survival. The absence of caveolin-1 in the stroma is strongly associated with more aggressive disease and reduced progression-free survival.
The IMPAKT Breast Cancer Conference is a groundbreaking collaboration between the European Society for Medical Oncology and Susan G. Komen for the Cure to accelerate breast cancer research. The conference aims to bring together world leaders in translational research to discuss cutting-edge treatments.
A study published in the American Journal of Roentgenology found that 3T MRI detected 66 malignant lesions, while mammography detected 54 and sonography detected 57. This suggests that 3T MRI is an important tool for early breast cancer detection and more accurate disease evaluation.
A novel gene called DEAR1 is associated with increased risk of local recurrence in young women with breast cancer. The discovery could lead to a new prognostic marker and guide treatment decisions.
A new gene called DEAR1 has been found to be genetically altered in breast tumors and may provide a new prognostic marker for breast cancer patients, particularly those with early-onset cancer. The research suggests that DEAR1-negative staining could help identify young women at high risk of cancer recurrence.
New research highlights large disparities in breast cancer care and treatment for African-American women, with a significantly lower five-year survival rate compared to Caucasian women. Socioeconomic barriers also hinder access to advanced treatments.
Richard Junghans, MD, has been awarded a $5.9 million grant from the Department of Defense Breast Cancer Research Program to research gene therapy techniques to modify patients' T cells and create 'designer T cells' to fight breast cancer.
A Michigan State University researcher has discovered a key hormone found in fat tissue that promotes tumor growth and cancer progression. Abdominal fat is associated with the greatest risk for cancer, particularly breast, colon, and endometrial cancers.
A brief intervention program boosted the number of women performing breast self-exams by tenfold, with 59% participating in adequate exams after one year. The program's success highlights the potential for simple interventions to improve health behaviors.
A study by Japanese researchers found that a molecule called M-CSF can be used to block the formation of new blood vessels in tumors, suppressing growth even after treatment is stopped. This approach differs from existing VEGF-based treatments, which have been shown to have limited long-term effects.
Researchers propose trial designs to investigate the impact of physical activity and weight control on breast cancer risk, with potential causal relationships. Clusterin is identified as a tumor suppressor gene in mouse models of neuroblastoma, where its expression affects tumor growth and metastasis.
Research found that women with tumors carrying TOP2A gene alterations had better outcomes when treated with anthracycline-based regimens, similar to those seen in HER2-positive tumors. The study suggests that TOP2A gene alteration is associated with increased benefit from anthracycline therapy.
Researchers have discovered a way to trigger an improved immune response to cancer using a combination of interleukin-7 and a viral vaccine. The new approach shows promise in treating cancer, potentially sparing patients from toxic therapies.
In a phase II study, lapatinib demonstrated efficacy in treating patients with inflammatory breast cancer, with 49% experiencing a partial response to the treatment. The median overall survival for responding patients was 18.4 months, significantly longer than non-responders.
A new report reveals a significant increase in the number of people diagnosed with cancer in Ireland, but also shows that survival rates are rising for certain types of cancer. The report highlights the importance of prevention and early detection in reducing the burden of cancer.
A new imaging technique called breast elastography enables accurate diagnoses of breast cancer by analyzing tissue stiffness. This study found that breast elastography outperformed conventional ultrasound in diagnosing breast cancers, reducing unnecessary biopsies and patient anxiety.
A study from the Medical College of Wisconsin found that the removal of more than five lymph nodes and presence of cancer in the lymph nodes are key factors linked to lymphedema. The study suggests that all women undergoing axillary surgery should be counseled on their risk for lymphedema.
A new MR procedure using diffusion-weighted imaging (DWI) can correctly identify 50 of 60 malignant lesions and 23 of 25 benign lesions, potentially reducing false-positive rates. This technique may help save women from unnecessary breast biopsies by characterizing benign from malignant lesions.
A new computer algorithm assesses mammographic breast density by automatically segmenting breast tissue from background, removing muscle, and using region growing to determine dense areas. This method provides objective and accurate recommendations on further imaging or monitoring, reducing variability among radiologists.